• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Adalimumab use results in high clinical response rate in hidradenitis suppurativa

byShayna BejaimalandShaidah Deghan, MSc. MD
August 5, 2016
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this phase 3 study, 40mg adalimumab weekly resulted in significantly greater improvement in abscess and inflammatory-nodule count with no increase in abscess or draining-fistula at 12 weeks of follow-up.

2. The rates of serious adverse events were similar across groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Hidradenitis suppurativa is a multinodular painful, chronic inflammatory skin disease. As the condition progresses there may also be abscesses and fistulas. Unfortunately, there are not many effective options for treatment. The PIONEER I and II trials looked at the impact of adalimumab, an antibody against tumour necrosis factor α (TNF- α), for hidradenitis suppurativa. This study describes the phase 3 results from this trial to determine if adalimumab shows efficacy against hidradenitis suppurativa.

Clinical response rates at 12 weeks of follow-up were statistically improved in the groups receiving weekly adalimumab as compared to placebo. Those randomized to adalimumab also had greater improvement in secondary outcomes such as lesions, pain, and the modified Sartorius score for disease severity. Serious adverse events were not statistically significant across groups. Limitations of this study include use of a composite outcome (“clinical response”) to determine the primary outcome. Also, the pharmaceutical sponsor was involved in data collection, analysis and interpretation. They also were involved with writing, reviewing and approving this manuscript and thus interpretation of results must be appraised with this in mind.

Click to read the study, published today in NEJM

Relevant Reading: Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis

RELATED REPORTS

#VisualAbstract: Patients report high satisfaction rates with clinic-based hidradenitis suppurativa surgery

#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa

#VisualAbstract: Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa

In-Depth [randomized controlled trial]: PIONEER I and II are multi-centre, randomized, double-blind, placebo-controlled trials. The study population included 633 patients at 101 sites in 14 countries with moderate to severe hidradenitis suppurativa who have not been on a TNF- α blocker. They were randomized to placebo or weekly 40 mg adalimumab. The primary efficacy end point was proportion of patients with clinical response at week 12. Clinical response was defined as Hidradenitis Suppurativa Clinical Response measure of at least 50% reduction from baseline in total abscess and inflammatory nodule count with no increase in abscess or draining fistula count. Outcomes were analyzed in an intention-to-treat fashion, between group differences were analyzed using the Cochran-Mantel-Haenszel test.

At week 12, groups assigned to adalimumab had significantly greater improvement in clinical response than placebo (41.8% vs. 26.0% in PIONEER I, p = 0.003; 58.9% vs. 27.6% in PIONEER II, p < 0.001). There was also improvement in the secondary outcomes of lesions, pain and modified Sartorius score for disease severity. Serious adverse events were 4.6% or less in all groups in both studies with no significant between-group differences.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Hidradenitis suppurativa
Previous Post

Higher incidence of germline DNA-repair mutations in men with metastatic prostate cancer

Next Post

Oral contraceptive use associated with increased risk of alveolar osteitis

RelatedReports

#VisualAbstract: Patients report high satisfaction rates with clinic-based hidradenitis suppurativa surgery
StudyGraphics

#VisualAbstract: Patients report high satisfaction rates with clinic-based hidradenitis suppurativa surgery

January 14, 2022
#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa
StudyGraphics

#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa

December 23, 2021
#VisualAbstract: Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa
StudyGraphics

#VisualAbstract: Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa

September 8, 2021
Hidradenitis suppurativa associated with increased risk of subclinical atherosclerosis
Dermatology

New prevalence estimates for hidradenitis suppurativa in the United States

June 3, 2017
Next Post
Oral contraceptive use associated with increased risk of alveolar osteitis

Oral contraceptive use associated with increased risk of alveolar osteitis

Accessibility, social norms associated with continued e-cigarette use among youth

Use of plant-based therapies and menopausal symptoms

Expansion of healthcare coverage associated with increased primary care utilization and quality

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
  • High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options